QUALITY OF LIFE OF PATIENTS WITH OVARIAN CANCER OF THE THIRD STAGE USING DIFFERENTIATED TREATMENT

The aim of this research was to assess the quality of life in patients with stage III ovarian cancer during the treatment period, depending on the applied therapeutic approaches. A comparative analysis of the results of treatment of 350 patients with adenocarcinoma of the ovaries of III-IV stage, which have undergone suboptimal or non-optimal cytomelective surgery, was conducted. To assess the quality of life and to examine the relationship between changes in physical health and quality of life, patients in both groups were asked to complete the questionnaires EORTC QLQ-C30 and SF-36. According to the questionnaire of the EORTC QLQ-C30, the indicators of physical activity, the ability to do everyday affairs, were higher in the second group of patients who received differentiated treatment. The indicator of "social functioning" was also higher in the II group of patients. When evaluating the patients' liver on the scale of the questionnaire SF-36, it was found that the positive effect of differentiated therapy is maintained for 3 years. Life quality is an important criterion for evaluating the results of antitumor therapy, and when it is continuously monitored in patients with ovarian cancer the safety of treatment for patients could be improved, including at an advanced stage

Quality of life among ovarian cancer survivors in Haji Adam Malik General Hospital Medan, Indonesia

Health Science Journal of Indonesia ◽

10.22435/hsji.v11i2.3080 ◽

2020 ◽

Vol 11 (2) ◽

pp. 133-139

Author(s):

Kristivani Br Ginting ◽

Muhammad Rizki Yaznil ◽

M. Oky Prabudi ◽

Lili Rahmawati

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Cancer Survivors ◽

General Hospital ◽

Detection Methods ◽

Cross Sectional ◽

Eortc Qlq C30 ◽

C 30 ◽

Latar belakang: Kanker ovarium memiliki angka mortalitas yang cukup tinggi dikarenakan gejalanya yang tidak spesifik, sering ditemukan pada stadium lanjut, dan belum adanya metode deteksi dini yang sudah terbukti. Untuk menilai keberhasilan terapi penyintas kanker ovarium, tidak hanya dinilai dari aspek klinis tetapi juga dinilai dari kualitas hidup penyintas kanker ovarium yang penilaiannya berdasarkan skala fungsional dan skala gejala dalam kuesioner EORTC QLQ C30 dan EORTC QLQ OV28. Metode: Penelitian ini menggunakan desain penelitian cross sectional, menggunakan data primer dari hasil wawancara dengan kuesioner EORTC QLQ C30 dan EORTC QLQ OV28 serta data sekunder yang berasal dari rekam medik di RSUP Haji Adam Malik Medan tahun 2017 - 2018. Sampel penelitian dipilih dengan metode total sampling dari seluruh data rekam medik yang memenuhi kriteria penelitian. Hasil: Hasil penelitian ini didapatkan kualitas hidup global penyintas kanker ovarium 89.36% adalah baik, dan 10.64% adalah sedang serta tidak ada yang memiliki kualitas hidup buruk. Namun, didapatkan adanya gangguan pada skala fungsional berupa: fungsi emosional, fungsi kognitif, fungsi seksual, dan sikap terhadap penyakit, serta adanya permasalahan pada skala gejala berupa: kelelahan, nyeri, neuropati perifer, dan gejala menopause. Didapatkan juga tidak ada hubungan karakteristik usia, jenis histopatologis, stadium, lama terapi dengan kualitas hidup penyintas kanker ovarium, namun terdapat hubungan antara jenis terapi dengan kualitas hidup penyintas kanker ovarium. Kesimpulan: Kualitas hidup penyintas kanker ovarium secara global adalah baik. Kata Kunci: Kualitas Hidup, Penyintas Kanker Ovarium, EORTC QLQ C-30, EORTC QLQ OV-28 Abstract Background: Ovarian cancer has a high mortality rate due to nonspecific symptoms, often found at an advanced stage, and also the absence of proven early detection methods. To assess the success of ovarian cancer survivors therapy, it is not only assessed from the clinical aspect but also from the quality of life of ovarian cancer survivors which is based on the functional and symptom scale in the EORTC QLQ C30 and EORTC QLQ OV28 questionnaires. Methods: This study used a cross-sectional study design, using primary data from interviews with the survivors based on the questionnaire EORTC QLQ C30 and EORTC QLQ OV28 as well as secondary data derived from medical records at Haji Adam Malik General Hospital Medan in 2017 - 2018. The research sample was used with a total sampling method from all medical record data that fulfill the research criteria. Result: The quality of life of ovarian cancer survivors is generally good (89.36%), meanwhile the rest is moderate (10.64%) without the poor quality of life. However, there are disorders on the functional scale in the form of emotional function, cognitive function, sexual function, and attitude toward disease. Likewise on the scale of symptoms, there are problems including: fatigue, pain, peripheral neuropathy, and menopausal symptoms. Conclusion: The quality of life of ovarian cancer survivors globally is good. Keywords: Quality of Life, Ovarian Cancer Survivors, EORTC QLQ C-30, EORTC QLQ OV-28

Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2001.19.5.1266 ◽

2001 ◽

Vol 19 (5) ◽

pp. 1266-1274 ◽

Cited By ~ 140

Author(s):

Catherine Doyle ◽

Michael Crump ◽

Melania Pintilie ◽

Amit M. Oza

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Palliative Chemotherapy ◽

Advanced Ovarian Cancer ◽

Patient Expectations ◽

Global Function ◽

Emotional Function ◽

Eortc Qlq C30 ◽

PURPOSE: The value of palliative chemotherapy in women with refractory and recurrent ovarian cancer is difficult to quantify, and little is known about patient expectations from these treatments. We evaluated in the current prospective study patient expectations, palliative outcomes of chemotherapy, and the inherent resource utilization in patients undergoing second- or third-line chemotherapy for recurrent or refractory advanced ovarian cancer. METHODS: The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (EORTC QLQ C30) and Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaires were used to assess palliative benefit and an in-house questionnaire was used to gauge patient expectations. The minimal clinically important difference (MCID) was calculated by asking women to make a global rating of change and correlating this to the EORTC QLQ C30. Resource use was recorded and costs were calculated. RESULTS: Twenty-seven patients were accrued. Objective response was documented on seven of 27. The median survival was 11 months. Sixty-five percent of women expected that chemotherapy would make them live longer and 42% that it would cure them. After two cycles, quality-of-life (QL) improvement was seen particularly in global function (11 of 21) and emotional function (13 of 21) with EORTC QLQ C-30. Improvement was sustained for a median of 2 and 3 months, respectively, in these categories. The MCID was calculated to be 0.39 on a seven-point scale for physical function and 0.13 for global function. The mean total cost per patient for the study period was Can $12,500. CONCLUSION: Patient expectations from these treatments are often unrealistic. Although objective responses are low, active palliation with chemotherapy is associated with substantive improvement in patients’ emotional function and global QL, with overall costs that seem relatively modest.

The relationship between global and specific components of quality of life, assessed with the EORTC QLQ-C30 in a sample of 2019 cancer patients

European Journal of Cancer Care ◽

10.1111/ecc.12416 ◽

2015 ◽

Vol 26 (2) ◽

pp. e12416 ◽

Cited By ~ 12

Author(s):

A. Hinz ◽

A. Mehnert ◽

C. Dégi ◽

D.R. Reissmann ◽

D. Schotte ◽

...

Keyword(s):

Quality Of Life ◽

Cancer Patients ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

PCN148 Estimating Quality of Life in Advanced Melanoma; A Comparison of Standard Gamble, SF-36 Mapped, and Eortc QLQ-C30 Mapped Utilities

Value in Health ◽

10.1016/j.jval.2011.08.1249 ◽

2011 ◽

Vol 14 (7) ◽

pp. A461-A462 ◽

Cited By ~ 3

Author(s):

A.J. Batty ◽

D. Fisher ◽

B. Winn ◽

Q. Wang ◽

K. Tolley ◽

...

Keyword(s):

Quality Of Life ◽

Standard Gamble ◽

Advanced Melanoma ◽

Sf 36 ◽

Eortc Qlq C30 ◽

Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin’s lymphoma (RR-NHL).

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e20070 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e20070-e20070

Author(s):

Vincent Lin ◽

Bhagyashree Oak ◽

Julia Snider ◽

Josh Epstein

Keyword(s):

Quality Of Life ◽

Literature Review ◽

B Cell Lymphoma ◽

Health Utility ◽

Current Standard ◽

Sf 36 ◽

Patient Reported ◽

Eortc Qlq C30 ◽

e20070 Background: CAR T therapy is being investigated as 2nd line therapy in RR-DLBCL. To evaluate its impact on patients’ HRQOL, it is essential to understand the HRQOL of patients receiving current standard of care (SOC) therapy for DLBCL and NHL patients. Methods: A systematic literature review (SLR) of studies reporting HRQOL in RR-DLBCL patients was conducted in March 2019 (updated to include RR-NHL in May 2019) using EMBASE, MEDLINE, Cochrane (all from 2007), Northern Light and International Society for Quality of Life Research abstracts (both from 2017). A targeted literature review (TLR) for untreated or 1st line patients was conducted in July 2019 using PubMed. Search terms included diseases, lines of therapy and patient-reported outcome (PRO) measures. Abstracts and publications were screened for eligibility and data were extracted. Results: Of the 977 publications screened for the SLR, 26 met the inclusion criteria. Another 18 studies were included from the TLR. The most commonly used PRO measures were the SF-36 (10 studies), EORTC QLQ-C30 and FACT-Lym (8 studies each). The EORTC QLQ-C30 showed statistically significant or clinically meaningful changes in a greater number of domains (86%) than the FACT-Lym (75%) and SF-36 (62%). Additional results in table. Conclusions: While research is limited, RR-DLBCL patients receiving current SOC therapy report decreases in HRQOL and health utility. Further research is needed on how existing and future therapies may affect HRQOL among RR-DLBCL patients. [Table: see text]

The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer

British Journal of Cancer ◽

10.1038/sj.bjc.6604248 ◽

2008 ◽

Vol 98 (5) ◽

pp. 888-893 ◽

Cited By ~ 55

Author(s):

M McKernan ◽

D C McMillan ◽

J R Anderson ◽

W J Angerson ◽

R C Stuart

Keyword(s):

Quality Of Life ◽

Oesophageal Cancer ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

Physical activity, fatigue and quality of life in breast cancer patients

Revista da Associação Médica Brasileira ◽

10.1590/1806-9282.62.01.38 ◽

2016 ◽

Vol 62 (1) ◽

pp. 38-44 ◽

Cited By ~ 14

Author(s):

Ana Carla Gomes Canário ◽

Patricia Uchoa Leitão Cabral ◽

Lucila Corsino de Paiva ◽

Gilzandra Lira Dantas Florencio ◽

Maria Helena Spyrides ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Physical Activity ◽

Activity Levels ◽

Breast Cancer Patients ◽

Physically Active ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

SUMMARY Objective: to evaluate the relationship between levels of physical activity, fatigue and quality of life (QOL) in women diagnosed with breast cancer. Methods: 215 women between the ages of 40 and 65 years were recruited at a cancer clinic. Physical activity levels were assessed by using the International Physical Activity Questionnaire (IPAQ), fatigue levels by using the revised Piper scale, and QOL by means of EORTC QLQ-C30 and WHOQOL-Bref. Statistical analysis was performed using Minitab statistical software, version 16. Results: the mean age of subjects was 52.66 years (SD=8.6); patients were mostly white (58.14%) and overweight (55.81%). Most women were fatigued (72.09%) while physically active women showed lower symptoms of fatigue (p<0.001). Mean scores for QOL were significantly lower among fatigued women (p<0.001). More active women scored higher on all scales of QOL (EORTC), especially for functional capacity (p<0.001), compared with the sedentary patients. A significant association was found between level of physical activity and overall QOL (WHOQOL-Bref) for all domains (p<0.001). Climacteric symptoms ranged from mild to strong and did not show any statistically significant results; however, the most active women had the fewest symptoms. Conclusion: physical activity appears to positively influence fatigue and QOL in women diagnosed with breast cancer.

Quality of Life in Breast and Colon Cancer Long-term Survivors: An Assessment with the Eortc Qlq-c30 and Sf-36 Questionnaires

Tumori Journal ◽

10.1177/030089160208800206 ◽

2002 ◽

Vol 88 (2) ◽

pp. 110-116 ◽

Cited By ~ 53

Author(s):

Paola Mosconi ◽

Giovanni Apolone ◽

Sandro Barni ◽

Simona Secondino ◽

Alberto Sbanotto ◽

...

Keyword(s):

Quality Of Life ◽

Colon Cancer ◽

Sf 36 ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

Long Term Survivors

Empirical Criteria for the Selection of Quality-of-Life Instruments for the Evaluation of Peripheral Blood Progenitor Cell Transplantation

International Journal of Technology Assessment in Health Care ◽

10.1017/s0266462300011405 ◽

1998 ◽

Vol 14 (3) ◽

pp. 419-430 ◽

Cited By ~ 3

Author(s):

Henry A. Glick ◽

Elizabeth J. Shpall ◽

C. F. LeMaistre ◽

Thomas J. McCarron ◽

Z. John Lu ◽

...

Keyword(s):

Quality Of Life ◽

Peripheral Blood ◽

Convergent Validity ◽

Progenitor Cell ◽

Peripheral Blood Progenitor Cell ◽

Sf 36 ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

Quality Of Life Instruments

AbstractWe propose a method for selecting quality-of-life instruments for use in phase III trials using the convergent validity of patient responses collected in phase I and II clinical trials.Two generic and two disease-specific instruments were administered to patients with breast cancer undergoing peripheral blood progenitor cell mobilization and transplantation. They included the visual analog scale from the EuroQoL EQ5D instrument, the SF-36, the European Organization for Research and Treatment of Cancer (EORTC)-QLQ-C30, and the Functional Assessment of Cancer Therapy instrument. No single instrument was found to have superior convergent validity in all domains, but the EORTC-QLQ-C30 seemed to perform better than the SF-36.